AstraZeneca recalled 916 pre-filled syringes of Fasenra on October 8, 2025. The recall follows a lack of assurance of sterility, posing serious health risks. Consumers and healthcare providers must stop using the product immediately.
Lack of Assurance of Sterility:
Consumers and healthcare providers should stop using this product immediately. Contact ASTRAZENECA PHARMACEUTICALS or your healthcare provider for guidance. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Fasenra (benralizumab) Injection, 30 mg/mL, is a prescription-only product. It is packaged in single-dose pre-filled syringes with NDC 0310-1730-30. The recalled product includes Lot YJ0152, which expires on January 31, 2028.
The recall stems from a lack of assurance of sterility, which can lead to serious infections. This issue is classified as Class II by the FDA, indicating a high level of risk.
There have been no reported injuries or deaths associated with this recall. However, the potential for serious health consequences remains a concern.
Stop using the recalled product immediately. Contact AstraZeneca Pharmaceuticals or your healthcare provider for guidance. Consumers can notify AstraZeneca via email.
For more information, visit the AstraZeneca website or contact their customer service directly. Additional details can be found at the FDA recall notification page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.